Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biologics
Hospira Launches Biologics "Clock" and Web Resource to Raise Awareness of Potential Biogenerics' Imapct
June 27th, 2009
Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, launched a clock tracking real-time U.S. prescription sales of costly biologic drugs as part of an informational Web resource highlighting the potential impact of biogenerics – generic versions of biologics – on the U.S. healthcare system. Although biogenerics are widely available in Europe and other parts of the world today, there is currently no legislative pathway allowing the U.S. Food and Drug Administration (FDA) to approve these safe, cost-effective alternatives for Americans. "As the first U.S. company to launch a biogeneric medicine in Europe, Hospira brings unique expertise to...
Source: Law & Health Weekly (2009-06-27)
|
